<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Risk factors for bleeding with anticoagulant therapy and estimated risk of major bleeding in low, moderate, and high risk categories</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Risk factors for bleeding with anticoagulant therapy and estimated risk of major bleeding in low, moderate, and high risk categories</h1>
<div class="graphic"><div class="figure"><div class="ttl">Risk factors for bleeding with anticoagulant therapy and estimated risk of major bleeding in low, moderate, and high risk categories</div><div class="cntnt"><table cellspacing="0"><colgroup span="4" width="25%"></colgroup> <tbody> <tr> <td class="subtitle1_left" colspan="4">Risk factors*</td> </tr> <tr> <td class="indent1" colspan="4"> <ul> <li>Age &gt;65 years</li> <li>Age &gt;75 years</li> <li>Previous bleeding</li> <li>Cancer</li> <li>Metastatic cancer</li> <li>Renal failure</li> <li>Liver failure</li> <li>Thrombocytopenia</li> <li>Previous stroke</li> <li>Diabetes</li> <li>Anemia</li> <li>Antiplatelet therapy</li> <li>Poor anticoagulant control</li> <li>Comorbidity and reduced functional capacity</li> <li>Recent surgery<sup>¶</sup></li> <li>Frequent falls</li> <li>Alcohol abuse</li> </ul> </td> </tr> <tr> <td class="subtitle1" colspan="4">Estimated absolute risk of major bleeding (%)</td> </tr> <tr> <td class="subtitle2">Categorization<br/> of risk of bleeding<sup>Δ</sup></td> <td class="subtitle2">Low risk<sup>◊</sup><br/> (0 risk factors)</td> <td class="subtitle2">Moderate risk<sup>◊</sup><br/> (1 risk factor)</td> <td class="subtitle2">High risk<sup>◊</sup><br/> (≥2 risk factors)</td> </tr> <tr> <td class="subtitle3_left_align" colspan="4">Anticoagulation 0 to 3 months<sup>§</sup></td> </tr> <tr> <td class="indent1">Baseline risk (%)</td> <td class="centered">0.6</td> <td class="centered">1.2</td> <td class="centered">4.8</td> </tr> <tr> <td class="indent1">Increased risk (%)</td> <td class="centered">1</td> <td class="centered">2</td> <td class="centered">8</td> </tr> <tr> <td class="indent1">Total risk (%)</td> <td class="centered">1.6<sup>§</sup></td> <td class="centered">3.2</td> <td class="centered">12.8<sup>¥</sup></td> </tr> <tr> <td class="subtitle3_left_align" colspan="4">Anticoagulation after first 3 months<sup>‡</sup></td> </tr> <tr> <td class="indent1">Baseline risk (%/years)</td> <td class="centered">0.3<sup>†</sup></td> <td class="centered">0.6</td> <td class="centered">≥2.5</td> </tr> <tr> <td class="indent1">Increased risk (%/years)</td> <td class="centered">0.5</td> <td class="centered">1</td> <td class="centered">≥4</td> </tr> <tr> <td class="indent1">Total risk (%/years)</td> <td class="centered">0.8**</td> <td class="centered">1.6**</td> <td class="centered">≥6.5</td> </tr> </tbody></table></div><div class="graphic_footnotes"><p>GI: gastrointestinal; UFH: unfractionated heparin; LMWH: low molecular weight heparin; VKA: vitamin K-dependent antagonist (ie, warfarin); VTE: venous thromboembolism.</p>
<p>* The increase in bleeding associated with a risk factor will vary with (1) severity of the risk factor (eg, location and extent of metastatic disease, platelet count), (2) temporal relationships (eg, interval from surgery or a previous bleeding episode), and (3) how effectively a previous cause of bleeding was corrected (eg, upper-GI bleeding).</p>
<p>¶ Important for parenteral anticoagulation (eg, first 10 days), but less important for long-term or extended anticoagulation.</p>
<p>Δ Although there is evidence that risk of bleeding increases with the prevalence of risk factors, this categorization scheme has not been validated. Furthermore, a single risk factor, when severe, will result in a high risk of bleeding (eg, major surgery within the past 2 days, severe thrombocytopenia).</p>
<p>◊ Compared with low-risk patients, moderate-risk patients are assumed to have a 2-fold risk and high-risk patients an 8-fold risk of major bleeding.</p>
<p>§ The 1.6% corresponds to the average of major bleeding with initial UFH or LMWH therapy followed by VKA therapy. We estimated baseline risk by assuming a 2.6 relative risk of major bleeding with anticoagulation (refer to footnote ‡).</p>
<p>¥ Consistent with frequency of major bleeding observed by Hull et al in high-risk patients<sup>[1]</sup>.</p>
<p>‡ We estimate that anticoagulation is associated with a 2.6-fold increase in major bleeding based on comparison of extended anticoagulation with no extended anticoagulation. The relative risk of major bleeding during the first 3 months of therapy may be greater than during extended VKA therapy because (1) the intensity of anticoagulation with initial parenteral therapy may be greater than with VKA therapy; (2) anticoagulant control will be less stable during the first 3 months; and (3) predispositions to anticoagulant-induced bleeding may be uncovered during the first 3 months of therapy. However, studies of patients with acute coronary syndromes do not suggest a ≥2.6 relative risk of major bleeding with parenteral anticoagulation (eg, UFH or LMWH) compared with control.</p>
<p>† Our estimated baseline risk of major bleeding for low-risk patients (and adjusted up for moderate- and high-risk groups as per footnote ◊).</p>
** Consistent with frequency of major bleeding during prospective studies of extended anticoagulation for VTE.</div><div class="graphic_reference">Reference:
<ol>
<li>Hull RD, Raskob GE, Rosenbloom D, et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med 1990; 322:1260.</li>
</ol>
<p class="extra_spacing_top">Reproduced from: Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e419S. Table used with the permission of Elsevier Inc. All rights reserved.</p></div><div id="graphicVersion">Graphic 97160 Version 5.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
